Investigator Uma Suryadevara, MD

Dr. Suryadevara had her medical education at Osmania Medical College, her residency at the University of Nevada, School of Medicine and specialized in Oncology and Hematology with her fellowship at the University of New Mexico. She specialized in benign hematology, breast cancer and gynecologic cancer. She values building trusting relationships with her patients and considers it a privilege and solemn responsibility to be part of their advocacy team. She listens and not just hears her patients and open to negotiating goals of care.

Sutter Health Research Enterprise
2001 Dwight Way
Berkeley, CA, 94704
(510) 204-1591
suryadu@sutterhealth.org

Primary Research Interests

Related Clinical Trials

Adjuvant (Alliance A191901) Temp Hold

Additional Support Program Via Text Messaging and Telephone-Based Counseling for Breast Cancer Patients Receiving Hormonal Therapy

Investigator: Uma Suryadevara MD

Status: Active, Not Recruiting

Commands

ACE-536 VS.Epoetin Alfa for the TX of Anemia Due to IPSS-R Very Low,Low or Intermediate Risk MDS in ESA Naïve Subjects Who Require RBC Transfusions

Investigators: Oleg I. Krijanovski M.D., Ph.D., Uma Suryadevara MD

Status: Active, Recruiting

Connect

Connect® MDS/AML Disease Registry

Investigators: Rajesh Behl M.D., Oleg I. Krijanovski M.D., Ph.D., Uma Suryadevara MD

Status: Active, Recruiting

Locally Advanced or Metastatic (Alliance A082002)

Testing the Addition of RT to the Usual Treatment (Immunotherapy +/- Chemotherapy) for Stage IV Non-Small Cell Lung Cancer Patients Who Are PD-L1 Negative

Investigator: Uma Suryadevara MD

Status: Active, Recruiting

Metastatic (Alliance A032001)

Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Trmt, Avelumab, in Pts With Metastatic Urothelial Cancer, MAIN-CAV Study

Investigator: Uma Suryadevara MD

Status: Active, Recruiting

Myelofibrosis (INCB 50465-304)

A Randomized, Double-Blind, Placebo-Controlled Study of the PI3Kd Inhibitor Parsaclisib Plus Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal

Investigators: Rajesh Behl M.D., Oleg I. Krijanovski M.D., Ph.D., Uma Suryadevara MD

Status: Active, Recruiting

Myelofibrosis (INCB 50465-313)

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of PI3Kd Inhibitor Parsaclisib and Ruxolitinib in Participants With Myelofibros

Investigators: Rajesh Behl M.D., Oleg I. Krijanovski M.D., Ph.D., Uma Suryadevara MD

Status: Active, Recruiting